Comprehensive Stock Comparison
Compare Inhibrx Biosciences, Inc. (INBX) vs Agios Pharmaceuticals, Inc. (AGIO) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth | AGIO | 48.0% revenue growth vs INBX's -88.9% |
| Quality / Margins | AGIO | -9.0% net margin vs INBX's -110.8% |
| Stability / Safety | INBX | Beta 0.74 vs AGIO's 0.91 |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) | INBX | +459.5% vs AGIO's -14.9% |
| Efficiency (ROA) | AGIO | -29.0% ROA vs INBX's -87.4% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
Inhibrx Biosciences is a clinical-stage biopharmaceutical company developing novel biologic therapeutics for life-threatening conditions like cancer. It generates no revenue currently — funding operations through equity offerings and partnerships while advancing multiple candidates through clinical trials. Its competitive advantage lies in proprietary single-domain antibody (sdAb) technology platforms that enable creation of multi-specific biologics with potentially superior therapeutic profiles.
Agios Pharmaceuticals is a biopharmaceutical company focused on developing treatments for rare genetic diseases related to cellular metabolism. It generates revenue primarily from sales of its lead drug PYRUKYND for pyruvate kinase deficiency — with additional income from research collaborations and milestone payments — while advancing a pipeline of other metabolic therapies. The company's competitive advantage lies in its deep expertise in cellular metabolism science and proprietary platform for targeting metabolic pathways in rare diseases.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
AGIO leads in 3 of 6 categories (Financial Metrics, Valuation Metrics). INBX leads in 2 (Total Returns, Risk & Volatility).
Financial Metrics (TTM)
AGIO is the larger business by revenue, generating $45M annually — 32.0x INBX's $1M. AGIO is the more profitable business, keeping -9.0% of every revenue dollar as net income compared to INBX's -110.8%.
| Metric | INBXInhibrx Bioscienc… | AGIOAgios Pharmaceuti… |
|---|---|---|
| RevenueTrailing 12 months | $1M | $45M |
| EBITDAEarnings before interest/tax | -$151M | -$470M |
| Net IncomeAfter-tax profit | -$155M | -$401M |
| Free Cash FlowCash after capex | -$143M | -$414M |
| Gross MarginGross profit ÷ Revenue | -86.3% | +84.4% |
| Operating MarginEBIT ÷ Revenue | -110.0% | -10.6% |
| Net MarginNet income ÷ Revenue | -110.8% | -9.0% |
| FCF MarginFCF ÷ Revenue | -102.5% | -9.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +43.7% |
| EPS Growth (YoY)Latest quarter vs prior year | +19.7% | -111.0% |
Valuation Metrics
| Metric | INBXInhibrx Bioscienc… | AGIOAgios Pharmaceuti… |
|---|---|---|
| Market CapShares × price | $1.1B | $2.25T |
| Enterprise ValueMkt cap + debt − cash | $930M | $2.25T |
| Trailing P/EPrice ÷ TTM EPS | 0.64x | -4.25x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 5373.68x | 9999.00x |
| Price / BookPrice ÷ Book value/share | 8.03x | 1.47x |
| Price / FCFMarket cap ÷ FCF | — | — |
Profitability & Efficiency
AGIO delivers a -31.2% return on equity — every $100 of shareholder capital generates $-31 in annual profit, vs $-4 for INBX. AGIO carries lower financial leverage with a 0.03x debt-to-equity ratio, signaling a more conservative balance sheet compared to INBX's 0.06x. On the Piotroski fundamental quality scale (0–9), INBX scores 4/9 vs AGIO's 3/9, reflecting mixed financial health.
| Metric | INBXInhibrx Bioscienc… | AGIOAgios Pharmaceuti… |
|---|---|---|
| ROE (TTM)Return on equity | -4.2% | -31.2% |
| ROA (TTM)Return on assets | -87.4% | -29.0% |
| ROICReturn on invested capital | — | -26.6% |
| ROCEReturn on capital employed | -169.3% | -33.8% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 3 |
| Debt / EquityFinancial leverage | 0.06x | 0.03x |
| Net DebtTotal debt minus cash | -$145M | -$49M |
| Cash & Equiv.Liquid assets | $153M | $89M |
| Total DebtShort + long-term debt | $8M | $40M |
| Interest CoverageEBIT ÷ Interest expense | -16.21x | — |
Total Returns (with DRIP)
A $10,000 investment in INBX five years ago would be worth $25,954 today (with dividends reinvested), compared to $6,363 for AGIO. Over the past 12 months, INBX leads with a +459.5% total return vs AGIO's -14.9%. The 3-year compound annual growth rate (CAGR) favors INBX at 46.1% vs AGIO's 6.1% — a key indicator of consistent wealth creation.
| Metric | INBXInhibrx Bioscienc… | AGIOAgios Pharmaceuti… |
|---|---|---|
| YTD ReturnYear-to-date | -1.2% | +11.2% |
| 1-Year ReturnPast 12 months | +459.5% | -14.9% |
| 3-Year ReturnCumulative with dividends | +211.6% | +19.4% |
| 5-Year ReturnCumulative with dividends | +159.5% | -36.4% |
| 10-Year ReturnCumulative with dividends | +263.5% | -21.2% |
| CAGR (3Y)Annualised 3-year return | +46.1% | +6.1% |
Risk & Volatility
INBX is the less volatile stock with a 0.74 beta — it tends to amplify market swings less than AGIO's 0.91 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. INBX currently trades 78.4% from its 52-week high vs AGIO's 65.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | INBXInhibrx Bioscienc… | AGIOAgios Pharmaceuti… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.74x | 0.91x |
| 52-Week HighHighest price in past year | $94.56 | $46.00 |
| 52-Week LowLowest price in past year | $10.81 | $22.24 |
| % of 52W HighCurrent price vs 52-week peak | +78.4% | +65.7% |
| RSI (14)Momentum oscillator 0–100 | 47.2 | 62.3 |
| Avg Volume (50D)Average daily shares traded | 165K | 948K |
Analyst Outlook
Wall Street rates INBX as "Buy" and AGIO as "Buy".
| Metric | INBXInhibrx Bioscienc… | AGIOAgios Pharmaceuti… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | — | $41.50 |
| # AnalystsCovering analysts | 5 | 29 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 0 | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Aug 20 | Feb 26 | Change |
|---|---|---|---|
| Inhibrx Biosciences… (INBX) | 100 | 398.59 | +298.6% |
| Agios Pharmaceutica… (AGIO) | 100 | 70.82 | -29.2% |
Inhibrx Biosciences… (INBX) returned +160% over 5 years vs Agios Pharmaceutica… (AGIO)'s -36%. A $10,000 investment in INBX 5 years ago would be worth $25,954 today (including dividends reinvested).
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Inhibrx Biosciences… (INBX) | $7M | $200000.00 | -97.0% |
| Agios Pharmaceutica… (AGIO) | $70M | $54M | -22.7% |
Agios Pharmaceuticals, Inc.'s revenue grew from $70M (2016) to $54M (2025) — a -2.8% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Inhibrx Biosciences… (INBX) | -124.0% | 8437.9% | +6903.1% |
| Agios Pharmaceutica… (AGIO) | -2.8% | -7.6% | -169.0% |
Agios Pharmaceuticals, Inc.'s net margin went from -3% (2016) to -8% (2025).
Chart 4EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Inhibrx Biosciences… (INBX) | -0.23 | 116.58 | +50787.0% |
| Agios Pharmaceutica… (AGIO) | -5.07 | -7.12 | -40.4% |
Agios Pharmaceuticals, Inc.'s EPS grew from $-5.07 (2016) to $-7.12 (2025).
Chart 5Free Cash Flow — 5 Years
Inhibrx Biosciences, Inc. generated $-197M FCF in 2024 (-143% vs 2021). Agios Pharmaceuticals, Inc. generated $-377M FCF in 2025 (+9% vs 2021).
INBX vs AGIO: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Is INBX or AGIO a better buy right now?
Inhibrx Biosciences, Inc. (INBX) offers the better valuation at 0.6x trailing P/E, making it the more compelling value choice. Analysts rate Inhibrx Biosciences, Inc. (INBX) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — INBX or AGIO?
Over the past 5 years, Inhibrx Biosciences, Inc. (INBX) delivered a total return of +159.5%, compared to -36.4% for Agios Pharmaceuticals, Inc. (AGIO). A $10,000 investment in INBX five years ago would be worth approximately $26K today (assuming dividends reinvested). Over 10 years, the gap is even starker: INBX returned +263.5% versus AGIO's -21.2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — INBX or AGIO?
By beta (market sensitivity over 5 years), Inhibrx Biosciences, Inc. (INBX) is the lower-risk stock at 0.74β versus Agios Pharmaceuticals, Inc.'s 0.91β — meaning AGIO is approximately 23% more volatile than INBX relative to the S&P 500. On balance sheet safety, Agios Pharmaceuticals, Inc. (AGIO) carries a lower debt/equity ratio of 3% versus 6% for Inhibrx Biosciences, Inc. — giving it more financial flexibility in a downturn.
04Which has better profit margins — INBX or AGIO?
Inhibrx Biosciences, Inc. (INBX) is the more profitable company, earning 8438% net margin versus -764.0% for Agios Pharmaceuticals, Inc. — meaning it keeps 8438% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AGIO leads at -873.9% versus -1657.2% for INBX. At the gross margin level — before operating expenses — AGIO leads at 88.3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — INBX or AGIO?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is INBX or AGIO better for a retirement portfolio?
For long-horizon retirement investors, Inhibrx Biosciences, Inc. (INBX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.74), +263.5% 10Y return). Both have compounded well over 10 years (INBX: +263.5%, AGIO: -21.2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between INBX and AGIO?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. In terms of investment character: INBX is a small-cap deep-value stock; AGIO is a mega-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.